Core Outcome Measures in Effectiveness Trials

Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group

General Information

Abstract:
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group recently published the updated 2016 psoriatic arthritis (PsA) core domain set, a set of disease features that should be measured in all clinical trials. At the GRAPPA annual meeting in July 2016, the PsA working group presented the updated PsA core domain set endorsed by 90% of participants at OMERACT in May 2016 and drafted a roadmap for the development of the PsA core outcome measurement set. In this manuscript, we review the development process of the PsA core domain set and the ongoing and proposed work streams for development of a PsA core measurement set.

Authors:
Ogdie, A. de Wit, M. Callis Duffin, K. Campbell, W. Chau, J. Coates, L. C. Eder, L. Elmamoun, M. FitzGerald, O. Gladman, D. D. Goel, N. James, J. Kalyoncu, U. Latella, J. Lindsay, C. Mease, P. J. O'Sullivan, D. Steinkoenig, I. Strand, V. Tillett, W. Orbai, A. M.

Publication

Journal:
J Rheumatol
Volume:
44
Issue:
5
Pages:
697 - 700
Year:
2017
DOI:
Further Study Information

Date:
Funding source(s):

Health Area

Disease Category
Rheumatology

Disease Name
Psoriatic arthritis

Target Population

Age Range
-

Sex
Unknown


Nature / type of Intervention
Unknown

Method(s)

Delphi process
Focus group(s)
Nominal group technique (NGT)
Semi structured discussion
Systematic review

Stakeholders Involved

Clinical experts
Consumers (patients)
Methodologists
Researchers

Study Type

COS for clinical trials or clinical research

The site uses cookies, some may have been set already. Please refer to our privacy policy & cookie usage statement.
If you continue to use the site we'll assume you're happy to accept the cookies.